The approach would apply to Pfizer's request for a licence to develop the COVID-19 tool.
In terms of the Scheme the board that wants the sale meets its costs, and it's not Pfizer's.
Even the RAP board would would say no to a question: "Oh, we want to buy your company. Would you mind meeting the expenses?"